Galderma, a global healthcare company that manufactures Restylane® and Dysport®, announced on July 2nd that they have received FDA approval to market Restylane® Lift for volume loss in the cheek area in patients over 21.
Restylane® Lyft was formerly marketed as Perlane-L®, an injectable used to smooth wrinkles in the face and restore volume. With this new indication, Restylane® Lyft is the first and only FDA approved filler indicated to provide fullness to the mid-face and to smooth the folds around the mouth (nasolabial folds).
“Consumers are looking for safe, high quality products that can deliver natural-looking results. This new indication demonstrates the versatility of Restylane® Lyft and its efficacy in addressing smile lines and restoring structure to the cheeks and midface area,” said Kelly Huang, Ph.D., Vice President and General Manager of Galderma’s Aesthetic and Corrective Business Unit in the U.S. “With more than 15 years of proven safety data and approximately 6 million treatments worldwide, Restylane® Lyft is a trusted, safe and effective product and we are proud to be able to expand our offering to healthcare providers and consumers in the U.S.”
Galderma changed the brand name from Perlane-L® to Restylane® Lyft to help health care providers and patients understand where it fits among other products in the Restylane® family (Restylane and Restylane Silk).
A clinical trail involving 200 patients showed improvement fullness in the midface area at 2 months in 88.7% of patients treated with Restylane® Lyft. Additionally, 95% of patients reported improvement at 2 months following treatment and 73% reported improvement at 12 months. Adverse events with treatment include redness and tenderness at injection site as well as bruising and swelling. Most reactions resolved within 2 weeks.
For more information, visit www.restylanelyft.com. Call (801)776-2220 to schedule a complimentary consultation with Dr. Scott Thompson in Layton, Bountiful, or Draper to see if Restylane Lyft is right for you.